TEZCAT Laboratories LLC

New Haven, CT · Biotech · Private

TZT-102, a macropinocytosis-selective monobody conjugate carrying a cytotoxic payload for treating mutant RAS multiple myeloma

Grants
$2.1M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A novel monobody-drug conjugate to treat mutant Ras multiple myeloma$399,877
Federal grantDepartment of Health and Human Services · Phase I · A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.$608,701
Federal grantDepartment of Health and Human Services · Phase II · A novel monobody-drug conjugate to treat mutant Ras multiple myeloma$1,062,082
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2955Diasome Pharmaceuticals, Inc.—$50M
2956ONCOCEUTICS, INC.——
2957INTEGRATED ANIMAL RESEARCH LLC——
2958TEZCAT Laboratories LLC——
2959Korsana Biosciences——
2960ONE-DERINGS LLC——
2961THERMOCAP LABORATORIES INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.